122 related articles for article (PubMed ID: 22101133)
1. Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.
Lachance N; Guiral S; Huang Z; Leclerc JP; Li CS; Oballa RM; Ramtohul YK; Wang H; Wu J; Zhang L
Bioorg Med Chem Lett; 2012 Jan; 22(1):623-7. PubMed ID: 22101133
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.
Lachance N; Gareau Y; Guiral S; Huang Z; Isabel E; Leclerc JP; Léger S; Martins E; Nadeau C; Oballa RM; Ouellet SG; Powell DA; Ramtohul YK; Tranmer GK; Trinh T; Wang H; Zhang L
Bioorg Med Chem Lett; 2012 Jan; 22(2):980-4. PubMed ID: 22209206
[TBL] [Abstract][Full Text] [Related]
3. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.
Uto Y; Ogata T; Harada J; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Deguchi T; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Abe M; Kurikawa N; Kawamura S; Yamato M; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4151-8. PubMed ID: 19540759
[TBL] [Abstract][Full Text] [Related]
4. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.
Uto Y; Ogata T; Kiyotsuka Y; Miyazawa Y; Ueno Y; Kurata H; Deguchi T; Yamada M; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Konishi M; Kurikawa N; Kono K; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4159-66. PubMed ID: 19541482
[TBL] [Abstract][Full Text] [Related]
5. Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Koltun DO; Zilbershtein TM; Migulin VA; Vasilevich NI; Parkhill EQ; Glushkov AI; McGregor MJ; Brunn SA; Chu N; Hao J; Mollova N; Leung K; Chisholm JW; Zablocki J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4070-4. PubMed ID: 19577469
[TBL] [Abstract][Full Text] [Related]
6. Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.
Leclerc JP; Falgueyret JP; Girardin M; Guay J; Guiral S; Huang Z; Li CS; Oballa R; Ramtohul YK; Skorey K; Tawa P; Wang H; Zhang L
Bioorg Med Chem Lett; 2011 Nov; 21(21):6505-9. PubMed ID: 21924609
[TBL] [Abstract][Full Text] [Related]
7. Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.
Ramtohul YK; Powell D; Leclerc JP; Leger S; Oballa R; Black C; Isabel E; Li CS; Crane S; Robichaud J; Guay J; Guiral S; Zhang L; Huang Z
Bioorg Med Chem Lett; 2011 Oct; 21(19):5692-6. PubMed ID: 21871798
[TBL] [Abstract][Full Text] [Related]
8. 2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.
Powell DA; Ramtohul Y; Lebrun ME; Oballa R; Bhat S; Falgueyret JP; Guiral S; Huang Z; Skorey K; Tawa P; Zhang L
Bioorg Med Chem Lett; 2010 Nov; 20(22):6366-9. PubMed ID: 20933412
[TBL] [Abstract][Full Text] [Related]
9. Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.
Isabel E; Powell DA; Black WC; Chan CC; Crane S; Gordon R; Guay J; Guiral S; Huang Z; Robichaud J; Skorey K; Tawa P; Xu L; Zhang L; Oballa R
Bioorg Med Chem Lett; 2011 Jan; 21(1):479-83. PubMed ID: 21074991
[TBL] [Abstract][Full Text] [Related]
10. SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.
Ramtohul YK; Black C; Chan CC; Crane S; Guay J; Guiral S; Huang Z; Oballa R; Xu LJ; Zhang L; Li CS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1593-7. PubMed ID: 20137926
[TBL] [Abstract][Full Text] [Related]
11. Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors.
Koltun DO; Parkhill EQ; Vasilevich NI; Glushkov AI; Zilbershtein TM; Ivanov AV; Cole AG; Henderson I; Zautke NA; Brunn SA; Mollova N; Leung K; Chisholm JW; Zablocki J
Bioorg Med Chem Lett; 2009 Apr; 19(7):2048-52. PubMed ID: 19249203
[TBL] [Abstract][Full Text] [Related]
12. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
[TBL] [Abstract][Full Text] [Related]
13. Stearoyl-CoA desaturase as a new drug target for obesity treatment.
Dobrzyn A; Ntambi JM
Obes Rev; 2005 May; 6(2):169-74. PubMed ID: 15836467
[TBL] [Abstract][Full Text] [Related]
14. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase.
Dobrzyn P; Dobrzyn A
Expert Opin Ther Pat; 2010 Jun; 20(6):849-53. PubMed ID: 20205608
[TBL] [Abstract][Full Text] [Related]
15. Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.
Powell DA; Black WC; Bleasby K; Chan CC; Deschenes D; Gagnon M; Gordon R; Guay J; Guiral S; Hafey MJ; Huang Z; Isabel E; Leblanc Y; Styhler A; Xu LJ; Zhang L; Oballa RM
Bioorg Med Chem Lett; 2011 Dec; 21(24):7281-6. PubMed ID: 22047692
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.
Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Yamada M; Deguchi T; Konishi M; Takagi T; Wakimoto S; Ohsumi J
Eur J Med Chem; 2010 Nov; 45(11):4788-96. PubMed ID: 20801551
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).
Léger S; Black WC; Deschenes D; Dolman S; Falgueyret JP; Gagnon M; Guiral S; Huang Z; Guay J; Leblanc Y; Li CS; Massé F; Oballa R; Zhang L
Bioorg Med Chem Lett; 2010 Jan; 20(2):499-502. PubMed ID: 20004097
[TBL] [Abstract][Full Text] [Related]
19. Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.
Li CS; Belair L; Guay J; Murgasva R; Sturkenboom W; Ramtohul YK; Zhang L; Huang Z
Bioorg Med Chem Lett; 2009 Sep; 19(17):5214-7. PubMed ID: 19632834
[TBL] [Abstract][Full Text] [Related]
20. Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Koltun DO; Vasilevich NI; Parkhill EQ; Glushkov AI; Zilbershtein TM; Mayboroda EI; Boze MA; Cole AG; Henderson I; Zautke NA; Brunn SA; Chu N; Hao J; Mollova N; Leung K; Chisholm JW; Zablocki J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3050-3. PubMed ID: 19394219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
